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Groundbreaking science often has its ups
and downs, especially when translating it
for clinical application. We have seen
before the so called “glitter-to-ashes” syn-
drome, where breakthrough science
makes its way into the headlines amidst
unreal expectations, there is a clinical dis-
appointment, and the technology is per-
ceived as being left in a smoldering heap
of unfulfilled promises. But here is where
the serious science just begins and the
ultimate fate of the technology gets decid-
ed. Antisense technology is a good case
in point. From being touted as the perfect
therapy to being a useless dream, we now
have about 40 antisense molecules in
clinical trial and one molecule (Vitravene,
Isis Pharmaceuticals) already FDA-
approved, having been shown to be effec-
tive against CMV retinitis.
Perhaps never before, however, has
any cancer therapy been as widely antici-
pated as the current wave of antiangio-
genic therapies now making their way
into the clinic. The concept is elegant in
its simplicity: inhibit the growth of geneti-
cally stable endothelial cells, and most
tumors should starve to death with little
acquired resistance. Glitter to ashes, as
we’ve come to expect, with early clinical
stumbles. But now the resurrection
begins with the recent approval of
Genentech’s Avastin, an antibody target-
ing VEGF-A and shown to extend the
lives of patients with advanced colorectal
carcinoma. A naturally occurring angio-
genesis antagonist, endostatin, first
shown to inhibit the growth of tumor
xenografts with no acquired resistance
(Boehm et al., 1997), has also had its ups
and downs (Jouanneau et al., 2001).
Now, in the latest issue of Molecular Cell
(Abdollahi et al., 2004), Peter Huber and
colleagues show that this protein alters
the expression of a bevy of factors con-
trolling angiogenesis, which may account
for its antiangiogenic activity in vivo.
The precise mechanism for the
antiangiogenic effect of endostatin has
been elusive. Endostatin, a C-terminal
fragment of collagen XVIII, has been
shown to block endothelial cell prolifera-
tion, survival, and migration, in part
through blocking VEGFR2 signaling, sup-
pressing Wnt signaling by β catenin desta-
bilization, or possibly altering β catenin/VE
cadherin interactions in interendothelial
cell junctions (for review see Dixelius 
et al., 2003). However, a unified model to
describe the multifaceted antiangiogenic
effect of endostatin has not been reported.
In their study, Abdollahi et al. have taken
advantage of gene profiling and protein
phosphorylation studies to determine the
global antiangiogenic effect of endostatin
on primary cultured human endothelial
cells. They provide evidence that endo-
statin induces its antiangiogenic effect
through regulation or modification of a
large cluster of genes known to affect
endothelial growth and development.
There are several remarkable
aspects of this detailed array analysis.
Approximately 12% of the 74,834 genes
on the chip have >2-fold alteration in
expression, either up or down, in
response to endostatin treatment. Of
these, 71 or 0.8% are known mediators of
angiogenesis. Strikingly, in the cases
reported, known proangiogenic factors
(such as Ids, HIF-1α, ephrins, and the
STATs) are all downregulated, and antian-
giogenic factors such as thrombospondin-
1 (TSP-1), kininogen, and a precursor of
vasostatin are all upregulated. The impli-
cation is that some of the genes affected
that are not known to be angiogenesis
regulators may in fact be, either directly or
indirectly. Remarkably, in many cases,
upstream regulators and downstream tar-
gets of these genes are affected in pre-
dicted ways. Using the Id analysis as an
example, it is observed that one potential
upstream regulatory pathway (namely
Ets-1, which upregulates Egr1, which in
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Up until now, the precise mechanism for endostatin’s antiangiogenesis action was not known. In a recent report, Abdollahi
et al. (2004) have taken advantage of gene array and proteomic analysis to map the antiangiogenic pathways turned on by
endostatin.This study resolves some of the controversies surrounding endostatin’s biology, and provides a new direction
to help dissect the molecular pathways involved in endostatin’s selective tumor antiangiogenic effects.
Figure 1. The angiogenic balance
Endostatin tips the scale toward angiogenesis inhibition by inhibiting the activity/expression of
proangiogenic factors and stimulating antiangiogenic factors both at the cell surface and
intracellularly. The arrows with question marks indicate our lack of understanding about signal-
ing interdependencies versus parallel effects of endostatin.
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turn controls Id1 gene expression in
response to serum [Ruzinova and
Benezra, 2003]) is downregulated upon
endostatin treatment concomitant with Id1
loss of expression. In addition, some
known downstream targets of Id1 loss
(namely HIF-1α reduction [Ruzinova et
al., 2003]) and elevation of TSP-1 [Volpert
et al., 2002]) are regulated as though Id1
loss is the primary event. Caution in the
interpretation of direct effects of Id loss
versus parallel effects of endostatin must
be exercised: loss of Id1 has been shown
to affect TSP-1 levels in Id1 knockout
fibroblasts, but no effects are observed in
tumor endothelial cells (Ruzinova et al.,
2003), suggesting parallel effects of endo-
statin signaling in the current study. Other
examples of this type of potential collabo-
rative networking exist in the analysis:
downregulation of the TNFR1 leading per-
haps to downregulation of Ephrin A1 via
attenuation of jnk and p38 signaling, and
NfkB signaling inhibited by reduced
expression and dephosphorylation and
downregulation of its targets, including
the antiapoptotic c-myc, iNOS, and Cox2.
More detailed analyses will be required to
distinguish between different possible
regulatory schemes (Figure 1).
There are other unresolved issues.
Endostatin may exert its antiangiogenic
effect through its binding to α5β1 integrin
and the consequent inhibition of matrix
adhesion and signaling (Wickstrom et al.,
2002), or low affinity binding to glycopi-
can-1 and glycopican-4 or as yet unidenti-
fied receptors (Karumanchi et al., 2001). It
is not obvious which endostatin receptor
conveys the antiangiogenic signals
described, but interestingly, many of the
genes upregulated by α5β1 engagement
and NfκB activation (Klein et al., 2002)
are downregulated by endostatin treat-
ment. A further complication is the study
referred to above showing that endostatin
interferes with VEGFR2 (KDR, Flk-1), the
tyrosine kinase receptor that is absolutely
essential for the proliferation, survival,
and migration of endothelial cells. The
gene profiling study by Abdollahi et al.
was performed with cultured primary
human dermal microvascular endothelial
(HDMVEC) cells that were maintained in
5% serum supplemented with endothelial
growth factors VEGF-A and FGF-2. As
serum contains antiangiogenic agents as
well (i.e., TSP-1 or TGF-β), it is possible
that endostatin may not directly induce
the expression of these antiangiogenic
agents delineated in this study, but rather
remove the trophic effect of proangiogenic
factors (i.e., VEGF-A), thereby shifting the
balance toward endothelial cell apoptosis.
Thus, the molecular resetting toward
endothelial cell death may be induced by
removal of proangiogenic factors rather
than by a direct induction of antiangio-
genic pathways.
Accumulating evidence also sug-
gests that tumor endothelial cells may
represent a phenotypically and function-
ally different type of endothelia. Abdollahi
et al. used primary HDMVEC treated for 4
hr with 200 ng/ml of endostatin. In con-
trast to other primary human endothelial
cells, only particular organ-specific ves-
sels, including brain and HDMVEC at
early passages, express CD36 (GPIV),
which is the cognate receptor for the
antiangiogenic factor TSP-1 (Bornstein,
2001; Lawler, 2002).Therefore, it remains
to be determined whether endostatin has
similar effects on other types of tumor-
derived endothelial cells or organ-specif-
ic microvascular endothelial cells.
One other as of yet unexplained but
remarkable phenomenon is that endo-
statin has no major effect on angiogene-
sis during wound healing, pregnancy, or
tissue reparative processes. As wound
healing is dependent on the recruitment
of dermal microvascular endothelial cells,
it remains to be determined why endo-
statin does not target HDMVECs during
this process. It is conceivable that unique
proangiogenic growth factors other than
VEGF-A or FGF-2 may override the
antiangiogenic effect of endostatin.
One approach to validate the data
generated by Abdollahi et al. would be to
isolate tumor endothelial cells from
implanted tumors immediately after
endostatin treatment. This will help iden-
tify genes that are activated de novo
selectively in tumor endothelial cells dur-
ing endostatin treatment. Comparison of
this gene profiling data with endostatin-
resistant endothelial cells present during
wound healing may provide an explana-
tion for the divergent effects of endo-
statin observed. In addition, evaluating
the effects of endostatin on spontaneous
tumor endothelium seems warranted
given the dramatic differences in effects
of antiangiogenic stress between
xenografts and genetic models of cancer
(Ruzinova et al., 2003).
Despite these considerations, the
report by Abdollahi et al. provides instruc-
tive road maps for future studies to 
understand the mechanism whereby
endostatin, or other antiangiogenic fac-
tors such as tumstatin, exert their potent
antiangiogenic effects under certain
pathophysiological conditions.There is no
doubt that endostatin targets selective
vascular niches dictated by the expres-
sion of its known and as of yet unidentified
receptors. Tumor vascular microenviron-
ment may be conducive to endostatin’s
antiangiogenic effects, as these endothe-
lial cells express functional endostatin
receptors or are dependent on angiogenic
growth factors whose receptors are tar-
geted by endostatin. This study by Huber
and colleagues has undoubtedly opened
up a new chapter in the intriguing antian-
giogenic biology of endostatin.
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